Delivery Order SPE2DB24D1205-SPE2DB25FDAKE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-tablet units, with a contract ceiling value of $13,740.06. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion on September 12, 2025, and will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $87,741.85 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30, with a firm fixed price arrangement. This non-set-aside competitive award was executed on September 2, 2025, with an ultimate completion date of September 3, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete transaction under...
- The Defense Logistics Agency awarded a delivery order valued at $8,025.05 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a small-value transaction under a larger federal...
- The Defense Logistics Agency awarded a delivery order valued at $51,847.92 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed-price contract type. This non-set-aside award was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The pharmaceutical products will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order represents a single...
- The Defense Logistics Agency awarded a delivery order valued at $22,621.69 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $3,198.50, was competitively awarded without set-aside designation and is scheduled for completion by August 22, 2025. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a $3,914.17 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for completion by August 18, 2025. The delivery order is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30 units, with a ceiling value of $92,797.95. This firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive set-aside procurement and is classified as a child contract,...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FDAKEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $60,140.57 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. This competitively awarded, firm fixed-price delivery order was executed on September 11, 2025, with an ultimate completion date of September 12, 2025. The contract requires performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside provisions applied to the award. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999.00 and extending through December 2026. This IDC enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, including medications, vaccines, and specialized medical commodities across multiple therapeutic domains. The arrangement reflects AmerisourceBergen's established role as a critical pharmaceutical vendor supporting Defense Health Agency and other federal healthcare systems, with the company positioned to potentially participate in DLA's next-generation Pharmaceutical Prime Vendor Global Program contracts planned for multiple regional awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $60.1k | 9/11/25 |